Personal information

Emails & domains

Verified email domains

Other IDs

Loop profile: 1611066

Keywords

Nanomedicine, Drug Delivery, Cancer Therapy, Antibody-Drug Conjugates, Targeted Therapeutics

Activities

Collapse all

Employment (5)

University of New South Wales Science: Sydney, NSW, AU

2023-04-03 to present | Conjoint Associate Lecturer (School of Clinical Medicine )
Employment
Source: Self-asserted source
Sara Mohamed

Children's Cancer Institute Australia: Randwick, New South Wales, AU

2022-10-03 to present | Research Officer (Leukaemia Biology )
Employment
Source: Self-asserted source
Sara Mohamed

Ain Shams University Faculty of Pharmacy: Cairo, EG

2016 to present | Assistant lecturer (Pharmaceuitcs and Industrial Pharmacy )
Employment
Source: Self-asserted source
Sara Mohamed

Children's Cancer Institute, UNSW, Australia: Randwick, New South Wales, AU

2018-07 to 2022-10 | PhD student
Employment
Source: Self-asserted source
Sara Mohamed

Ain Shams University Faculty of Pharmacy: Cairo, EG

2009 to 2016 | Teaching assisitant and reasearcher (Pharmaceutics and Industrial Pharmacy)
Employment
Source: Self-asserted source
Sara Mohamed

Education and qualifications (3)

University of New South Wales Discipline of Women's Health: Randwick, NSW, AU

2018-07 to 2022-12-14 | PhD student (Children's Cancer Institute, Leukemia Biology Group)
Education
Source: Self-asserted source
Sara Mohamed

Ain Shams University Faculty of Pharmacy: Cairo, EG

2011 to 2016 | Master (Drug Technology)
Education
Source: Self-asserted source
Sara Mohamed

Ain Shams University Faculty of Pharmacy: Cairo, EG

2003 to 2009 | Bachelor of Pharmaceutical Sciences
Education
Source: Self-asserted source
Sara Mohamed

Professional activities (6)

Controlled Release Society: Mount Laurel, New Jersey, US

2021-10 to 2022-10
Membership
Source: Self-asserted source
Sara Mohamed

Translational Cancer Research Network PhD Top-Up Scholarship: Sydney, NSW, AU

2021
Distinction
Source: Self-asserted source
Sara Mohamed

The Postgraduate Council in conjunction with Graduate Research School, University of New South Wales : Sydney, NSW, AU

2021 | Student Nominee Award
Distinction
Source: Self-asserted source
Sara Mohamed

Translational Cancer Research Network: Sydney , AU

2021 to 2021
Membership
Source: Self-asserted source
Sara Mohamed

Kids Cancer Alliance: Sydney , AU

2019 | PhD-TOP-UP Scholarship
Distinction
Source: Self-asserted source
Sara Mohamed

University of New South Wales - Randwick Campus: Randwick, NSW, AU

2018-07 | PhD Scholarship
Distinction
Source: Self-asserted source
Sara Mohamed

Funding (2)

CRLF2-Targeted Nanomedicine for the Treatment of Ph-like Paediatric Acute Lymphoblastic Leukaemia

2019-04 to 2020-04 | Award
Kids Cancer Alliance (Sydney, AU)
Source: Self-asserted source
Sara Mohamed

A novel antibody-drug conjugate for the treatment of a high-risk subtype of leukaemia in adults and children

Grant
NHMRC (Australia, AU)
Source: Self-asserted source
Sara Mohamed

Works (12)

The CD123 antibody–drug conjugate pivekimab sunirine exerts profound activity in preclinical models of pediatric acute lymphoblastic leukemia

HemaSphere
2025-01 | Journal article
DOI: 10.1002/hem3.70063
Part of ISSN: 2572-9241
Part of ISSN: 2572-9241
Contributors: Ben Watts; Christopher M. Smith; Kathryn Evans; Andrew J. Gifford; Sara M. A. Mohamed; Stephen W. Erickson; Eric J. Earley; Steven Neuhauser; Timothy M. Stearns; Vivek M. Philip et al.
Source: Self-asserted source
Sara Mohamed

TOPORS E3 ligase mediates resistance to hypomethylating agent cytotoxicity in acute myeloid leukemia cells

Nature Communications
2024-08-28 | Journal article
DOI: 10.1038/s41467-024-51646-6
Part of ISSN: 2041-1723
Contributors: Peter Truong; Sylvie Shen; Swapna Joshi; Md Imtiazul Islam; Ling Zhong; Mark J. Raftery; Ali Afrasiabi; Hamid Rokny; Mary Nguyen; Xiaoheng Zou et al.
Source: Self-asserted source
Sara Mohamed

An antibody fragment-decorated liposomal conjugate targets Philadelphia-like acute lymphoblastic leukemia

International Journal of Biological Macromolecules
2024-01 | Journal article
DOI: 10.1016/j.ijbiomac.2023.127596
Part of ISSN: 0141-8130
Contributors: Sara M.A. Mohamed; Peter Schofield; Hannah McCalmont; Ernest Moles; Karl-Heinz Friedrich; Maria Kavallaris; Daniel Christ; Narges Bayat; Richard B. Lock
Source: Self-asserted source
Sara Mohamed

In Vitro Evaluation of a Novel Antibody Fragment-Drug Conjugate Targeting Paediatric Philadelphia-Like Acute Lymphoblastic Leukaemia

12th International Nanomedicine Conference
2022-06-28 | Conference poster
Contributors: Sara Mohamed
Source: Self-asserted source
Sara Mohamed

A recombinant antibody fragment directed to the thymic stromal lymphopoietin receptor (CRLF2) efficiently targets pediatric Philadelphia chromosome-like acute lymphoblastic leukemia

International Journal of Biological Macromolecules
2021-11 | Journal article
DOI: 10.1016/j.ijbiomac.2021.08.194
Part of ISSN: 0141-8130
Source: Self-asserted source
Sara Mohamed

A Novel Antibody-Drug Conjugate for Targeting High-Risk Pediatric Leukemia

Controlled Release Society
2021-07 | Conference poster
Source: Self-asserted source
Sara Mohamed

Food to medicine transformation of stilbenoid vesicular and lipid-based nanocarriers: Technological advances

Drug Delivery Aspects
2020 | Book chapter
DOI: 10.1016/b978-0-12-821222-6.00011-7
Part of ISBN: 9780128212226
Source: Self-asserted source
Sara Mohamed

A Novel Engineered Single-Chain Antibody Fragment for Targeting Pediatric Philadelphia Chromosome-like Acute Lymphoblastic Leukemia

The American Society of Hematology
2020-12-06 | Conference poster
Source: Self-asserted source
Sara Mohamed

A Novel Engineered Single-Chain Antibody Fragment for Targeting Pediatric Philadelphia Chromosome-like Acute Lymphoblastic Leukemia

The American Society of Hematology
2020-11-05 | Conference abstract
Source: Self-asserted source
Sara Mohamed

Cytokine Receptor-Like Factor 2 Internalisation Indicates its Potential as a Therapeutic Target in Paediatric Philadelphia-Like Acute Lymphoblastic Leukaemia

Kids Cancer Alliance, Early Career Researchers (KCA ECR) Showcase
2020-09-17 | Conference poster
Source: Self-asserted source
Sara Mohamed

Terbinafine hydrochloride nanovesicular gel: In vitro characterization, ex vivo permeation and clinical investigation

European Journal of Pharmaceutical Sciences
2016-06 | Journal article
DOI: 10.1016/j.ejps.2016.04.004
Part of ISSN: 0928-0987
Source: Self-asserted source
Sara Mohamed

Dermal delivery of Terbinafine hydrochloride nano vesicular chitosan gel: In vitro characterization, ex vivo permeation and clinical investigation

The joint conference of the Canadian Society for Pharmaceutical Sciences (CSPS) and the Canadian Chapter of the Controlled Release Society (CC-CRS)
2015 | Conference poster
Source: Self-asserted source
Sara Mohamed

Peer review (1 review for 1 publication/grant)

Review activity for Biomedical microdevices. (1)
How many people are using ORCID?